HRP20191935T1 - Pripravci za stimuliranje matičnih stanica - Google Patents
Pripravci za stimuliranje matičnih stanica Download PDFInfo
- Publication number
- HRP20191935T1 HRP20191935T1 HRP20191935TT HRP20191935T HRP20191935T1 HR P20191935 T1 HRP20191935 T1 HR P20191935T1 HR P20191935T T HRP20191935T T HR P20191935TT HR P20191935 T HRP20191935 T HR P20191935T HR P20191935 T1 HRP20191935 T1 HR P20191935T1
- Authority
- HR
- Croatia
- Prior art keywords
- defensin
- cosmetic formulation
- topical cosmetic
- formulation according
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 25
- 210000000130 stem cell Anatomy 0.000 title claims 2
- 230000004936 stimulating effect Effects 0.000 title 1
- 102000000541 Defensins Human genes 0.000 claims 31
- 108010002069 Defensins Proteins 0.000 claims 31
- 239000002537 cosmetic Substances 0.000 claims 24
- 238000009472 formulation Methods 0.000 claims 24
- 230000000699 topical effect Effects 0.000 claims 24
- 230000037303 wrinkles Effects 0.000 claims 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 101710193393 Alpha-defensin 5 Proteins 0.000 claims 2
- 102100026887 Beta-defensin 103 Human genes 0.000 claims 2
- 101710125296 Beta-defensin 3 Proteins 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108010058846 Ovalbumin Proteins 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 229940014041 hyaluronate Drugs 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims 1
- 101710193402 Alpha-defensin 1 Proteins 0.000 claims 1
- 102100037437 Beta-defensin 1 Human genes 0.000 claims 1
- 101710125314 Beta-defensin 1 Proteins 0.000 claims 1
- 102100026886 Beta-defensin 104 Human genes 0.000 claims 1
- 101710125300 Beta-defensin 4 Proteins 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 claims 1
- 101710117153 Neutrophil defensin 2 Proteins 0.000 claims 1
- 102400001060 Neutrophil defensin 2 Human genes 0.000 claims 1
- 101710117152 Neutrophil defensin 3 Proteins 0.000 claims 1
- 102100024761 Neutrophil defensin 3 Human genes 0.000 claims 1
- 101710117154 Neutrophil defensin 4 Proteins 0.000 claims 1
- 102100036348 Neutrophil defensin 4 Human genes 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 241000212749 Zesius chrysomallus Species 0.000 claims 1
- 210000003486 adipose tissue brown Anatomy 0.000 claims 1
- 229960002648 alanylglutamine Drugs 0.000 claims 1
- 102000018568 alpha-Defensin Human genes 0.000 claims 1
- 108050007802 alpha-defensin Proteins 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 229940110767 coenzyme Q10 Drugs 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims 1
- 238000004885 tandem mass spectrometry Methods 0.000 claims 1
- 108010034266 theta-defensin Proteins 0.000 claims 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims 1
- 229940035936 ubiquinone Drugs 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- KRJOFJHOZZPBKI-KSWODRSDSA-N α-defensin-1 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CSSC[C@H](NC2=O)C(O)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 KRJOFJHOZZPBKI-KSWODRSDSA-N 0.000 claims 1
- ZKIAWZPHVZQYMG-QYJCGYSGSA-N θ-defensin Chemical compound O=C([C@@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CCCNC(N)=N)C(=O)N1)=O)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)[C@@H](C)CC)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]2CSSC1 ZKIAWZPHVZQYMG-QYJCGYSGSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
Claims (15)
1. Topikalna kozmetička formulacija, naznačena time što sadrži:
kozmetički prihvatljiv nosač u kombinaciji s prvim defenzinom;
gdje se prvi defenzin bira iz skupine koju čine α-defenzin 1, α-defenzin 5, α-defenzin 6, neutrofilni defenzin 2, neutrofilni defenzin 3, neutrofilni defenzin 4, θ-defenzin, β-defenzin 1, β-defenzin 3, te β-defenzin 4; i
gdje je prvi defenzin prisutan u topikalnoj kozmetičkoj formulaciji u koncentraciji nedjelotvornoj u inhibiranju mikrobnog rasta, te gdje je topikalna kozmetička formulacija topikalna kozmetička formulacija spremna za upotrebu.
2. Topikalna kozmetička formulacija u skladu s patentnim zahtjevom 1, naznačena time što je prvi defenzin inkapsuliran u liposom.
3. Topikalna kozmetička formulacija u skladu s patentnih zahtjeva 1 ili 2, naznačena time što prvi defenzin uključuje najmanje jedan od sintetskog defenzina, rekombinantnog defenzina, ljudskog defenzina, majmunskog defenzina, mišjeg defenzina, štakorskog defenzina, goveđeg defenzina, ovčjeg defenzina, konjskog defenzina, kunićjeg defenzina, svinjskog defenzina, psećeg defenzina, te mačjeg defenzina.
4. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je subantimikrobno djelotvorna koncentracija prvog defenzina u topikalnoj kozmetičkoj formulaciji spremnoj za upotrebu između 0,01 i (uključujući) 100 ng/ml.
5. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je koncentracija prvog defenzina u topikalnoj kozmetičkoj formulaciji spremnoj za upotrebu između 1 i (uključujući) 30 ng/ml.
6. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je koncentracija prvog defenzina u topikalnoj kozmetičkoj formulaciji spremnoj za upotrebu otprilike 22 ng/ml.
7. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je koncentracija prvog defenzina u topikalnoj kozmetičkoj formulaciji spremnoj za upotrebu otprilike 4,4 ng/ml.
8. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je prvi defenzin prisutan u topikalnoj kozmetičkoj formulaciji u koncentraciji koja je djelotvorna za bitno smanjivanje najmanje jednog od dubine bora, duljine bora, širine bora, veličine pora, nepravilnosti u teksturi površine kože, masnosti, smeđih mrlja, te crvenih mrlja u neozlijeđenoj koži.
9. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što prvi defenzin ima čistoću iznad 95%, kao što je prikazano uz pomoć HPLC, te gdje prvi defenzin ima slijed određen tandemnim MS/MS.
10. Topikalna kozmetička formulacija u skladu s bilo kojim od patentnih zahtjeva 2-9, naznačena time što liposom sadrži fosfolipid.
11. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je prvi defenzin povezan s proteinskim nosačem.
12. Topikalna kozmetička formulacija u skladu s patentnim zahtjevom 11, naznačena time što proteinski nosač sadrži najmanje jedan od ljudskog serumskog albumina, rekombinantnog albumina, goveđeg serumskog albumina, te albumina iz jaja.
13. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dodatno sadrži drugi defenzin, gdje se drugi defenzin razlikuje od prvog defenzina, te gdje je drugi defenzin prisutan u topikalnoj kozmetičkoj formulaciji u koncentraciji nedjelotvornoj u inhibiranju mikrobnog rasta.
14. Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dodatno sadrži dodatni sastojak za matične stanice LGR6+, gdje dodatni sastojak uključuje najmanje jedno od ljudskog serumskog albumina, rekombinantnog albumina, goveđeg serumskog albumina, albumina iz jaja, biljnog hidrolizata, β-ciklodekstrina, glutamina, fosfolipida, fibronektina, hijualuronata, hijualuronske kiseline, epidermalnog čimbenika rasta, čimbenika rasta fibroblasta, biljnog hidrolizata, l-alanil-l-glutamina, želatine, rekombinantne želatine, vitamina E, tokoferil-nikotinata, koenzima Q10, te ubikinona.
15. Topikalna kozmetička formulacija u skladu s patentnim zahtjevom 1, naznačena time što prvi defenzin uključuje najmanje jedan od α-defenzina 5 i β-defenzina 3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014044P | 2014-06-18 | 2014-06-18 | |
| EP15810115.4A EP3157504B1 (en) | 2014-06-18 | 2015-06-16 | Stem cell stimulating compositions |
| PCT/US2015/036049 WO2015195677A1 (en) | 2014-06-18 | 2015-06-16 | Stem cell stimulating compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191935T1 true HRP20191935T1 (hr) | 2020-05-15 |
Family
ID=54936047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211983TT HRP20211983T1 (hr) | 2014-06-18 | 2015-06-16 | Pripravci za i postupci stimuliranja matičnih stanica |
| HRP20191935TT HRP20191935T1 (hr) | 2014-06-18 | 2019-10-23 | Pripravci za stimuliranje matičnih stanica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211983TT HRP20211983T1 (hr) | 2014-06-18 | 2015-06-16 | Pripravci za i postupci stimuliranja matičnih stanica |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US11491096B2 (hr) |
| EP (2) | EP3586821B1 (hr) |
| CY (2) | CY1122333T1 (hr) |
| DK (2) | DK3586821T3 (hr) |
| ES (2) | ES2903108T3 (hr) |
| HR (2) | HRP20211983T1 (hr) |
| HU (1) | HUE057737T2 (hr) |
| LT (2) | LT3157504T (hr) |
| PL (2) | PL3586821T3 (hr) |
| PT (2) | PT3586821T (hr) |
| RS (1) | RS62981B1 (hr) |
| SI (1) | SI3586821T1 (hr) |
| WO (1) | WO2015195677A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3586821B1 (en) * | 2014-06-18 | 2021-12-01 | Medicell Technologies, LLC | Stem cell stimulating compositions and methods |
| SI3389620T1 (sl) | 2015-12-15 | 2023-01-31 | Medicell Technologies, Llc | Sestavki, ki stimulirajo izvorne celice in postopki zdravljenja melazme |
| WO2018013142A1 (en) * | 2016-07-15 | 2018-01-18 | Medicell Technologies Llc | Compositions and methods for providing hair growth |
| CN109692130B (zh) * | 2019-01-30 | 2022-06-21 | 威海同丰海洋生物科技有限公司 | 一种含有防御素的面膜液及其制备方法 |
| CN109718127B (zh) * | 2019-01-30 | 2022-08-09 | 荣成市吉海生物科技有限公司 | 一种非离子型杀菌消炎洗面奶及其制备方法 |
| CN109692129B (zh) * | 2019-01-30 | 2022-06-21 | 威海同丰海洋生物科技有限公司 | 一种含有防御素的剃须膏及其制备方法 |
| JP6735887B2 (ja) * | 2019-08-22 | 2020-08-05 | 富士フイルム株式会社 | 間葉系幹細胞の細胞老化抑制剤、間葉系幹細胞の細胞老化抑制用皮膚外用組成物、間葉系幹細胞の細胞老化抑制用機能性飲食品、及び間葉系幹細胞の細胞老化抑制方法 |
| IT202100018542A1 (it) * | 2021-07-14 | 2023-01-14 | Clever Bioscience S R L | Liposomi contenenti combinazioni antimicrobiche sinergiche a base di peptidi selezionati e acidi grassi |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3689668A (en) * | 1967-10-18 | 1972-09-05 | Emile Leon Piette | Method of alleviating wrinkles on skin |
| US5242902A (en) * | 1989-09-06 | 1993-09-07 | The Regents Of The University Of California | Defensin peptide compositions and methods for their use |
| FR2767832B1 (fr) * | 1997-08-29 | 2001-08-10 | Genset Sa | Polypeptide defensine humaine def-x, adn genomique et adnc, composition les contenant et applications au diagnostic et au traitement therapeutique |
| US6984622B2 (en) * | 1998-03-25 | 2006-01-10 | The Regents Of The University Of California | Use of lipopolysaccharides to manage corneal infections and wounds |
| EP1519750A2 (en) * | 2002-03-28 | 2005-04-06 | Exponential Biotherapies, Inc. | Oxygenating agents for enhancing host responses to microbial infections |
| US8119791B2 (en) * | 2003-12-17 | 2012-02-21 | Avon Products, Inc. | si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation |
| DE102005014687A1 (de) * | 2005-03-29 | 2006-10-12 | Henkel Kgaa | Zusammensetzung enthaltend ß-Defensin 2 |
| US8202835B2 (en) * | 2005-06-17 | 2012-06-19 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
| US7528107B2 (en) * | 2005-11-30 | 2009-05-05 | Auburn University | Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins |
| WO2008133928A2 (en) * | 2007-04-27 | 2008-11-06 | The Gi Company, Inc. | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders |
| DE102009044970A1 (de) * | 2009-07-23 | 2011-01-27 | Henkel Ag & Co. Kgaa | Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses |
| ES2384060B1 (es) * | 2010-03-24 | 2013-09-23 | Lipotec S.A. | Cápsulas de nanopartículas lipídicas. |
| US9034302B2 (en) * | 2011-04-11 | 2015-05-19 | L'oreal | Mineral sunscreen composition and process for protecting skin from photodamage and aging |
| WO2012155048A1 (en) * | 2011-05-11 | 2012-11-15 | Wisconsin Alumni Research Foundation | Liposome-encapsulated hydrogels for use in a drug delivery system |
| BR112013030874B8 (pt) * | 2011-06-02 | 2021-09-14 | Univ California | Uso de uma theta-defensina ou análogo da mesma para tratar uma condição inflamatória crônica |
| US20130310326A1 (en) * | 2012-05-18 | 2013-11-21 | Rapid Pathogen Screening, Inc. | Histatin for Corneal Wound Healing and Ocular Surface Disease |
| WO2014004339A2 (en) | 2012-06-25 | 2014-01-03 | Elc Management Llc | Method for stimulating cellular beta defensins |
| EP3586821B1 (en) * | 2014-06-18 | 2021-12-01 | Medicell Technologies, LLC | Stem cell stimulating compositions and methods |
| SI3389620T1 (sl) * | 2015-12-15 | 2023-01-31 | Medicell Technologies, Llc | Sestavki, ki stimulirajo izvorne celice in postopki zdravljenja melazme |
| WO2018013142A1 (en) * | 2016-07-15 | 2018-01-18 | Medicell Technologies Llc | Compositions and methods for providing hair growth |
-
2015
- 2015-06-16 EP EP19190130.5A patent/EP3586821B1/en active Active
- 2015-06-16 RS RS20220191A patent/RS62981B1/sr unknown
- 2015-06-16 PL PL19190130T patent/PL3586821T3/pl unknown
- 2015-06-16 HU HUE19190130A patent/HUE057737T2/hu unknown
- 2015-06-16 PT PT191901305T patent/PT3586821T/pt unknown
- 2015-06-16 SI SI201531800T patent/SI3586821T1/sl unknown
- 2015-06-16 WO PCT/US2015/036049 patent/WO2015195677A1/en active Application Filing
- 2015-06-16 HR HRP20211983TT patent/HRP20211983T1/hr unknown
- 2015-06-16 DK DK19190130.5T patent/DK3586821T3/da active
- 2015-06-16 ES ES19190130T patent/ES2903108T3/es active Active
- 2015-06-16 PL PL15810115T patent/PL3157504T3/pl unknown
- 2015-06-16 LT LT15810115T patent/LT3157504T/lt unknown
- 2015-06-16 EP EP15810115.4A patent/EP3157504B1/en active Active
- 2015-06-16 DK DK15810115T patent/DK3157504T3/da active
- 2015-06-16 ES ES15810115T patent/ES2754523T3/es active Active
- 2015-06-16 LT LTEP19190130.5T patent/LT3586821T/lt unknown
- 2015-06-16 PT PT158101154T patent/PT3157504T/pt unknown
-
2016
- 2016-12-19 US US15/383,423 patent/US11491096B2/en active Active
-
2019
- 2019-10-23 HR HRP20191935TT patent/HRP20191935T1/hr unknown
- 2019-11-01 CY CY20191101142T patent/CY1122333T1/el unknown
-
2022
- 2022-01-18 CY CY20221100042T patent/CY1125101T1/el unknown
- 2022-07-29 US US17/815,972 patent/US20220401337A1/en active Pending
- 2022-09-09 US US17/930,842 patent/US20230000750A1/en active Pending
- 2022-09-09 US US17/930,840 patent/US20230000749A1/en active Pending
- 2022-09-09 US US17/930,845 patent/US20230000751A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3586821T3 (da) | 2022-01-17 |
| EP3157504A4 (en) | 2018-01-03 |
| EP3586821A1 (en) | 2020-01-01 |
| US20230000750A1 (en) | 2023-01-05 |
| US20220401337A1 (en) | 2022-12-22 |
| WO2015195677A4 (en) | 2016-01-21 |
| CY1125101T1 (el) | 2023-06-09 |
| EP3157504A1 (en) | 2017-04-26 |
| PL3586821T3 (pl) | 2022-03-14 |
| WO2015195677A1 (en) | 2015-12-23 |
| RS62981B1 (sr) | 2022-03-31 |
| DK3157504T3 (da) | 2019-11-04 |
| EP3157504B1 (en) | 2019-08-07 |
| US20230000749A1 (en) | 2023-01-05 |
| SI3586821T1 (sl) | 2022-04-29 |
| US11491096B2 (en) | 2022-11-08 |
| PT3586821T (pt) | 2022-04-11 |
| CY1122333T1 (el) | 2021-01-27 |
| EP3586821B1 (en) | 2021-12-01 |
| HRP20211983T1 (hr) | 2022-08-19 |
| HUE057737T2 (hu) | 2022-06-28 |
| US20230000751A1 (en) | 2023-01-05 |
| ES2754523T3 (es) | 2020-04-20 |
| LT3586821T (lt) | 2022-03-25 |
| ES2903108T3 (es) | 2022-03-31 |
| PT3157504T (pt) | 2019-11-11 |
| PL3157504T3 (pl) | 2020-03-31 |
| US20170157015A1 (en) | 2017-06-08 |
| LT3157504T (lt) | 2019-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191935T1 (hr) | Pripravci za stimuliranje matičnih stanica | |
| BR112012031183A2 (pt) | líquidos nutricionais substancialmente claros compreendendo proteína de cálcio hmb e solúvel | |
| HRP20221425T1 (hr) | Sastavi za stimuliranje matičnih stanica i metode liječenja melazme | |
| HRP20201948T1 (hr) | Pripravci inhibitora dopa-dekarbokilaze | |
| Martín-Venegas et al. | The methionine precursor DL-2-hydroxy-(4-methylthio) butanoic acid protects intestinal epithelial barrier function | |
| AR094071A1 (es) | Composicion con precursores de haluros de zinc aminoacidos / trimetilglicina | |
| BR112018072064B8 (pt) | Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| MY182593A (en) | Composition containing chitin and digestible proteins | |
| WO2015006287A3 (en) | Compositions prepared from poultry and methods of their use | |
| BR112018067946A2 (pt) | formulações tópicas contendo ciclosporina e usos das mesmas | |
| EP3521306A4 (en) | FUSION PROTEIN INCLUDING AN IMMOBILIZED PROTEIN HAVING AN INCREASED ANTIOXIDANT FUNCTION, A SKIN CELL PROLIFERATION EFFECT, A HUMAN EPITHELIAL CELL GROWTH FACTOR HAVING AN ENHANCED ANTIOXIDIZING FUNCTION, A SKIN CELL PROLIFERATION EFFECT, A FACTOR FOR THE GROWTH OF HUMAN EPITHELIAL CELLS, AND A COSMETIC COMPOSITION CONTAINING PRINCIPE IN PRIPAUTEIN | |
| BR112016011489A2 (pt) | composição nutricional pediátrica com peptídeos do leite para crescimento e desenvolvimento saudável | |
| SG10201901656WA (en) | Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof | |
| BR112015000621A2 (pt) | composição cosmética compreendendo benzilsulfonil-d-ser-homophe-(4-amidino-benzilamida) e um poliálcool | |
| PH12016500025A1 (en) | Methods for promoting neuronal development and/or health | |
| HRP20201630T1 (hr) | Sastavi i postupci za liječenje kožnog t-staničnog limfoma | |
| RU2014104798A (ru) | Способы и композиции для улучшения качества волос с применением экстракта ежевики | |
| AR104721A1 (es) | Fragmento fab anti-ngf humano | |
| WO2015112866A3 (en) | Compounds and methods for increasing hair growth | |
| BR112018076229A2 (pt) | formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo | |
| MX2018011082A (es) | Péptido o aminoácido n-lipoico, derivados y sus usos. | |
| WO2013119144A3 (ru) | Средство для роста волос (варианты) и способ лечения облысения | |
| CN104983605A (zh) | 一种高效的保湿型爽肤水 | |
| BR112012020089A2 (pt) | formulações de retinol e métodos para utilização das mesmas |